Romero-Sánchez Laura, López-Freire Sara, González-Fernández Teresa, Méndez-Brea Paula
Servicio de Alergia, Complejo Hospitalario Universitario de Santiago de Compostela, España.
Rev Alerg Mex. 2023 Jan 4;69(2):101-104. doi: 10.29262/ram.v69i2.1026.
The cyclooxygenase-2 inhibitors are usually recommended as a safe alternative in patients with multiple hypersensitivity to non-steroidal antiinflammatory drugs. Nevertheless, both immediate and delayed hypersensitivity reactions have been described, and the possibility of cross-reactivity with sulphonamides.
A 66-year-old patient who, after taking a celecoxib tablet, presented with latency of several hours a skin reaction. Previously, he had presented a minor reaction during treatment with etoricoxib without establishing the correlation at that time. The patient underwent an allergological study by means of skin tests with negative results and an oral challenged test with etoricoxib with positive results. Tolerance to sulfonamides was proven.
We present a singular case of a cross-reactivity skin reaction to etoricoxib and celecoxib, suggesting the need to perform challenge tests to confirm the tolerance or not of each drug before allowing their use. On the contrary, trimethropim/sulfamethoxazole could be safely used in our patients, if needed.
对于对非甾体抗炎药有多种过敏反应的患者，环氧化酶-2抑制剂通常被推荐为一种安全的替代药物。然而，已经有速发型和迟发型过敏反应的报道，以及与磺胺类药物交叉反应的可能性。
一名66岁的患者在服用塞来昔布片后，数小时后出现皮肤反应。此前，他在使用依托考昔治疗期间出现过轻微反应，但当时未确定相关性。该患者通过皮肤试验进行了过敏学研究，结果为阴性，并进行了依托考昔口服激发试验，结果为阳性。已证实其对磺胺类药物耐受。
我们报告了一例对依托考昔和塞来昔布交叉反应性皮肤反应的特殊病例，提示在允许使用每种药物之前，有必要进行激发试验以确认其耐受性。相反，如果需要，甲氧苄啶/磺胺甲恶唑可在我们的患者中安全使用。
